RSS   Newsletter   Contact   Advertise with us

Johnson and Johnson initiates Phase 3 trial for coronavirus

Christian Fernsby ▼ | September 24, 2020
Johnson and Johnson said it has launched Phase 3 trial for its coronavirus vaccine candidate.
Johnson and Johnson
Coronavirus vaccine candidate   Johnson and Johnson
The trial will enroll up to 60,000 volunteers across three continents to study the safety and efficacy of a single vaccine dose versus placebo in preventing the novel coronavirus.

Topics: Johnson and Johnson

Chairman and CEO Alex Gorsky said in a statement the firm will hold "standards of safety" and "transparency" during the trial.

New Jersey-based company said it aims to provide one billion doses of a successful vaccine each year.

While delivery of a cure to millions of people around the world remains an issue, the firm said its vaccine, if successful, would not require new infrastructure to get it to the people who need it because it is expected to remain stable for two years at minus 20 degrees Celsius (minus 4 F).

Johnson and Johnson's coronavirus vaccine candidate will get help from a technology platform that was also used to develop and manufacture an approved Ebola vaccine and construct its HIV vaccine candidates.

The platform has been used to vaccinate more than 100,000 people to date across various vaccine programs.

With Janssen’s AdVac technology, the vaccine, if successful, is estimated at launch to remain stable for two years at -20 °C and at least three months at 2-8° C. This makes the vaccine candidate compatible with standard vaccine distribution channels and would not require new infrastructure to get it to the people who need it.